Hannah Hunter

2.4k citations

21 papers · 397 indexed · h-index 8

Impact in

Hematology top 5%
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
Genetics top 10%
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Hematology 15
- Multiple Myeloma Research and Treatments 9
- Acute Myeloid Leukemia Research 6
- Chronic Myeloid Leukemia Treatments 4
Genetics 6
- Chronic Lymphocytic Leukemia Research 4

Co-authors: Nigel H. Russell (5 shared papers)Martin Grundy (2 shared papers)Claire Seedhouse (2 shared papers)Monica Pallis (2 shared papers)Guy Pratt (3 shared papers)Jamie Cavenagh (6 shared papers)Gordon Cook (6 shared papers)John A. Snowden (7 shared papers)
Journals: Blood (6 papers)British Journal of Haematology (5 papers)Gene (1 paper)Bone Marrow Transplantation (1 paper)Leukemia (1 paper)
Partner nations: United Kingdom United States Germany

In The Last Decade

Hannah Hunter

20 papers receiving 395 citations

Peers

Countries citing papers authored by Hannah Hunter

Since Specialization

Citations

This map shows the geographic impact of Hannah Hunter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hannah Hunter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hannah Hunter more than expected).

Fields of papers citing papers by Hannah Hunter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hannah Hunter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hannah Hunter. The network helps show where Hannah Hunter may publish in the future.

Co-authors

The 25 scholars most cited alongside Hannah Hunter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hannah Hunter Line = papers co-authored together Hannah Hunter links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial The Lancet Haematology ·Gordon Cook, A. John Ashcroft, David A. Cairns, Cathy Williams, Julia Brown, Jamie Cavenagh, John A. Snowden, Christopher Parrish, Kwee Yong, Jim Cavet, Hannah Hunter, Jenny Bird, Guy Pratt, Sally Chown, Ernest Heartin, Sheila J.M. O’Connor, Mark T. Drayson, Anna Hockaday, T. C. M. Morris	2016	96
2	DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412 Leukemia ·Claire Seedhouse, Hannah Hunter, Bethan Lloyd‐Lewis, A. Massip, Monica Pallis, G I Carter, Martin Grundy, Shili Shang, Nigel H. Russell	2006	66
3	Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia British Journal of Haematology ·A. Agathocleous, A. Z. S. Rohatiner, Simon Rule, Hannah Hunter, Jonathan P. Kerr, S. Neeson, Janet Matthews, Sandra J. Strauss, Silvia Montoto, Peter Johnson, John Radford, Andrew Lister	2010	50
4	UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high‐dose chemoradiotherapy for patients with malignancy Journal of Clinical Apheresis ·Kenneth Douglas, Maria Gilleece, Patrick Hayden, Hannah Hunter, Peter Johnson, Charlotte Kallmeyer, Ram Malladi, Shankara Paneesha, Rachel Pawson, Michael Quinn, Kavita Raj, Deborah Richardson, Stephen Robinson, Nigel H. Russell, John A. Snowden, Anna Sureda, Eleni Tholouli, Kirsty Thomson, Mike Watts, Keith Wilson	2017	39
5	Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline British Journal of Haematology ·Jonathan Sive, Kirsty Cuthill, Hannah Hunter, Majid Kazmi, Guy Pratt, Dean Smith, (unknown)	2021	37
6	The expression of P‐glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors British Journal of Haematology ·Hannah Hunter, Monica Pallis, Claire Seedhouse, Martin Grundy, Claire Gray, Nigel H. Russell	2004	33
7	Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning – evidence for a superior outcome using melphalan combined with total body irradiation British Journal of Haematology ·Hannah Hunter, Karl S. Peggs, R Powles, Amin Rahemtulla, P Mahendra, Jamie Cavenagh, Tim Littlewood, Mike Potter, Ann Hunter, Antonio Pagliuca, C. D. Williams, Gordon Cook, K. Towlson, I. David, Nigel H. Russell	2005	32
8	Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenstrom’s Macroglobulinaemia. Blood ·A. Agathocleous, Simon Rule, Peter Johnson, John Radford, N. Lafon, Hannah Hunter, Jaclyn P. Kerr, S. Neeson, J. Matthews, Sandra J. Strauss, Silvia Montoto, A. Z. S. Rohatiner, Tim Lister	2007	10
9	Survivorship care for allogeneic transplant patients in the UK NHS: changes centre practice, impact of health service policy and JACIE accreditation over 5 years Bone Marrow Transplantation ·Fiona L. Dignan, Angela Hamblin, Amelia Chong, Jungwha Lee, Michelle Kenyon, P.D. Miller, Maria Gilleece, Hannah Hunter, John A. Snowden, (unknown), Kim Orchard, Deborah Richardson, Dominic Culligan, Kavita Raj, Eduardo Olavarría, Marie Waller, Bim Laguda, Rachael Hough, Ram Malladi, Jenny Byrne, Stephen Byrne	2020	7
10	Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial Biology of Blood and Marrow Transplantation ·Christopher Parrish, Curly Morris, Cathy Williams, David A. Cairns, Jamie Cavenagh, John A. Snowden, John Ashcroft, Jim Cavet, Hannah Hunter, Jenny Bird, A. Chalmers, Julia Brown, Kwee Yong, Steve Schey, Sally Chown, Gordon Cook	2016	6
11	A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial Blood ·Gordon Cook, Cathy Williams, David A. Cairns, Anna Hockaday, Jamie Cavenagh, John A. Snowden, Christopher Parrish, Kwee Yong, Jim Cavet, Hannah Hunter, Jennifer M. Bird, Guy Pratt, Sally Chown, Earnest Heartin, Sheila J.M. O’Connor, John Ashcroft, Julia Brown, Curly Morris	2015	4
12	Acute myeloid leukaemia: an unusual cause of biliary strictures BMJ Case Reports ·Adele Beck, Hannah Hunter, Simon Jackson, David Sheridan	2019	3
13	Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia Gene ·David Tucker, Malcolm Hamilton, Jaclyn P. Kerr, Caroline Wickham, Hannah Hunter	2012	3
14	Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The First Trial Blood ·Cyrille Hulin, Thierry Façon, Chaim Shustik, Andrew R. Belch, Maria Teresa Petrucci, Ulrich Dührsen, Jin Lu, Kevin Song, Philippe Rodon, Brigitte Pegourié, Laurent Garderet, Hannah Hunter, I Azaïs, Richard Eek, Margaret Macro, Shaker R. Dakhil, Vanessa Houck, Guang Chen, Annette Ervin‐Haynes, Fritz Offner	2014	3
15	Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT Blood ·Claire Burney, Stephen Robinson, Ariane Boumendil, Hervé Finel, Irma Khvedelidze, Hannah Hunter, Xavier Poiré, Bruno Lioure, Karl S. Peggs, Robin Foà, Srinivas Pillai, Tom van Meerten, Juan Bargay, Christoph Schmid, Vibeke Vergote, Arnold Ganser, Luca Castagna, Ghulam J. Mufti, Silvia Montoto	2019	2
16	Continuous Treatment With Lenalidomide and Low-Dose Dexamethasone for Patients With Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the First Trial: Impact of Age Clinical Lymphoma Myeloma & Leukemia ·Cyrille Hulin, Chaim Shustik, Andrew Belch, Maria Teresa Petrucci, Ulrich Dührsen, Jin Lu, Kevin Song, Philippe Rodon, Laurent Garderet, Hannah Hunter, I Azaïs, Richard Eek, Margaret Macro, Shaker R. Dakhil, Vanessa Houck, G. Chen, Annette Ervin‐Haynes, Fritz Offner, Meletios Α. Dimopoulos, Thierry Façon	2015	2
17	The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma Leukemia & lymphoma ·Michelle Furtado, Kathleen Clarke, Patrick Medd, Hannah Hunter, Simon Rule	2015	1
18	Detection of hepatitis b virus DNA in the blood of a stem cell donor after granulocyte colony‐stimulating factor treatment Hepatology ·Michael Punzel, Patrick Medd, Hannah Hunter, Richard Cunningham, Bryson Pottinger, Bernd Burde, Marek Widera, Annegret Quade, Gerhard Ehninger, Anna Kozlova, Helmuth Schmidt, Karin Buhrmann, Christian G. Schüttler, Dieter Glebe, Annelies Billen, Alexander H. Schmidt, Thilo Mengling, Jens Verheyen	2016	1
19	A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial Blood ·Gordon Cook, Cathy Williams, David A. Cairns, Marie Fletcher, Jamie Cavenagh, John A. Snowden, Christopher Parrish, John Ashcroft, Kwee Yong, Jim Cavet, Hannah Hunter, Jennifer M. Bird, Sheila J.M. O’Connor, Julia Brown, Curly Morris	2013	1
20	Immune Biomarkers Identify Sustained Quantitative and Functional Immune Reconstitution in the Setting of Adjunctive Lenalidomide Following T-Depleted RIC-Allo SCT for Multiple Myeloma Blood ·Gordon Cook, Clive R. Carter, Kristian Brock, Grant McQuaker, John A. Snowden, Charles Crawley, Hannah Hunter, Jamie Cavenagh, Mark Lobb, Katherine Cullen, Andrea Hodgkinson, Mirjana Sirovica, Mark Cook	2016	1

About Hannah Hunter

Hannah Hunter is a scholar working on Hematology, Genetics, Transplantation, Oncology and Pathology and Forensic Medicine, having authored 21 papers that have together received 397 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (9 papers), Acute Myeloid Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (4 papers), Protein Degradation and Inhibitors (4 papers), Chronic Myeloid Leukemia Treatments (4 papers), Chronic Lymphocytic Leukemia Research (4 papers), Cancer Treatment and Pharmacology (3 papers) and Viral-associated cancers and disorders (3 papers). The work is most often cited by research in Hematology (312 citations), Genetics (85 citations), Oncology (160 citations), Pathology and Forensic Medicine (63 citations) and Molecular Biology (202 citations). Hannah Hunter has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Nigel H. Russell, Martin Grundy, Claire Seedhouse, Monica Pallis, Guy Pratt, Jamie Cavenagh, Gordon Cook, John A. Snowden, Bethan Lloyd‐Lewis and Jim Cavet. Their work appears in journals such as Blood, British Journal of Haematology, Gene, Bone Marrow Transplantation and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact